Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: PET Clin. 2018 Jul;13(3):415–422. doi: 10.1016/j.cpet.2018.02.005

Figure 2.

Figure 2

Pre and post treatment images in patients treated with ER— blocking (A. Tamoxifen, B. Fulvestrant) and estrogen lowering therapies (C. aromatase inhibitor). Tumor in the upper spine shows complete ER blockade. Tumor in mediastinal nodes shows incomplete ER blockade. Sternal tumor shows no blockade.

From Linden HM, Kurland BF, Peterson LM, et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res. 2011;17:4799–4805; with permission.